Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Recap: Follow up: Regarding Topline Data From COVID-19 Study

www.globenewswire.com/news-release/2021/03/31/2202350/0/en/Algernon-Pharmaceuticals-Announces-Topline-Data-From-its-Phase-2b-3-COVID-19-Trial-of-Ifenprodil.html

Time in ICU:

Topline results for this endpoint indicate that there was also a strong trend to less time spent in the ICU in the overall study by patients in the 20 mg dose arm, as compared to patients in the untreated arm (adjusted hazard ratio 10.45, CI 1.23-88.61, p=0.0315).

However, the Company cautions that additional, confounding variables were detected, and these numbers need to be confirmed with additional analysis, as well as power calculations conducted to project the required size for a Phase 3 study.

Did we ever get an explanation for the above endpoint? The answer is N O. Just like we don't know what the Xrays suggest overall in the study.

Let me know when I'm not telling it like it is @ ihub AGNPF. Someone has to do it. Otherwise we all fall complacent to the straight up BS coming from the corporate office. Lack of receiving Actionable Information doesn't help the common shareholder or the CEO's leadership acumen.

Oh...does anyone remember how SMACKIE - MACKIE (DA PIMP) Research slammed Algernon after the Topline readout? SMACKIE said there was no statistically significant endpoints and Ph3 would be pointless. SMACKIE said Algernon needed to move on and focus on the IPF/CC study.

Remember that?

Well remember it also when the next PP book runner is SMACKIE MACKIE.

The Checkers not Chess "CEO" is in way over his head.

Period.

M$